VolitionRx (NYSE:VNRX) Coverage Initiated at StockNews.com

StockNews.com began coverage on shares of VolitionRx (NYSE:VNRX) in a research note released on Wednesday morning. The firm issued a sell rating on the stock.

Separately, Benchmark reissued a hold rating on shares of VolitionRx in a research report on Friday, August 16th.

VolitionRx Trading Up 3.0 %

NYSE VNRX opened at $0.58 on Wednesday. VolitionRx has a 12 month low of $0.43 and a 12 month high of $1.23. The stock has a 50 day moving average of $0.65 and a 200-day moving average of $0.70. The company has a market cap of $53.14 million, a PE ratio of -1.25 and a beta of 1.12.

VolitionRx (NYSE:VNRX) last announced its quarterly earnings data on Wednesday, August 14th. The company reported ($0.08) EPS for the quarter, beating analysts’ consensus estimates of ($0.09) by $0.01. The firm had revenue of $0.40 million during the quarter, compared to the consensus estimate of $0.34 million. As a group, sell-side analysts predict that VolitionRx will post -0.31 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, Director Guy Archibald Innes bought 150,000 shares of the business’s stock in a transaction dated Tuesday, August 20th. The stock was bought at an average price of $0.67 per share, for a total transaction of $100,500.00. Following the purchase, the director now owns 406,683 shares in the company, valued at approximately $272,477.61. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Company insiders own 12.80% of the company’s stock.

VolitionRx Company Profile

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.